Browse All

Current Filters

CLEAR FILTER x

TITLE

Author:

Ublituximab, a Novel, Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Enhanced Antibody-Dependent Cellular Cytotoxicity (ADCC) Relative to Other Anti-CD20 mAbs

Evaluating the Effect of Disease Duration in High Efficacy Versus Mid Efficacy Disease Modifying Therapies: Could This Help in Deciding When to De-escalate?

The Bruton’s Tyrosine Kinase Inhibitor Evobrutinib Demonstrates Superior Efficacy in Targeting Compartmentalized Neuroinflammation Compared to Anti-CD20 Treatment.